OPTUS Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	87,577	81,905	72,426	58,658	57,316	60,827
Other Revenue	-0	-0	-0	-	-	-
Revenue	87,577	81,905	72,426	58,658	57,316	60,827
Revenue Growth (YoY)	11.13%	13.09%	23.47%	2.34%	-5.77%	0.64%
Cost of Revenue	38,712	37,277	31,072	27,041	24,821	22,531
Gross Profit	48,865	44,628	41,354	31,617	32,495	38,296
Selling, General & Admin	35,622	32,846	30,623	24,138	20,589	21,588
Research & Development	1,437	1,883	1,384	1,343	1,110	821.84
Other Operating Expenses	292.8	260.69	164.19	184.49	110.92	107.83
Operating Expenses	38,611	36,119	33,168	26,368	22,023	23,489
Operating Income	10,254	8,509	8,187	5,249	10,472	14,808
Interest Expense	-75.82	-97.24	-124.4	-85.89	-8.88	-17.61
Interest & Investment Income	1,613	2,373	2,296	1,401	846.43	1,137
Currency Exchange Gain (Loss)	330.86	84.8	3.33	12.17	127.54	-17.39
Other Non Operating Income (Expenses)	-581.1	-469.62	11.79	21.69	-36.76	105.62
EBT Excluding Unusual Items	11,541	10,400	10,374	6,598	11,400	16,015
Gain (Loss) on Sale of Investments	1,158	1,242	1,967	73.39	-	2,505
Gain (Loss) on Sale of Assets	10.86	441.87	629.3	878.29	44.24	-18.97
Asset Writedown	-	-	-	-721.2	-964.98	-
Pretax Income	12,709	12,084	12,970	6,828	10,479	18,502
Income Tax Expense	1,526	1,776	2,210	1,816	587.88	4,097
Net Income	11,184	10,308	10,760	5,012	9,892	14,405
Net Income to Common	11,184	10,308	10,760	5,012	9,892	14,405
Net Income Growth	17.56%	-4.20%	114.69%	-49.33%	-31.33%	-1.31%
Shares Outstanding (Basic)	15	15	15	16	16	16
Shares Outstanding (Diluted)	15	15	15	16	16	16
Shares Change (YoY)	0.18%	0.48%	-4.18%	-1.07%	-0.62%	-1.20%
EPS (Basic)	731.00	674.99	708.00	316.00	617.00	893.00
EPS (Diluted)	731.00	674.99	708.00	316.00	617.00	893.00
EPS Growth	17.36%	-4.66%	124.05%	-48.78%	-30.91%	-0.11%
Free Cash Flow	-20,914	-2,903	9,109	-3,955	-3,557	11,603
Free Cash Flow Per Share	-1367.02	-190.11	599.36	-249.37	-221.87	719.32
Gross Margin	55.80%	54.49%	57.10%	53.90%	56.69%	62.96%
Operating Margin	11.71%	10.39%	11.30%	8.95%	18.27%	24.34%
Profit Margin	12.77%	12.59%	14.86%	8.54%	17.26%	23.68%
Free Cash Flow Margin	-23.88%	-3.55%	12.58%	-6.74%	-6.21%	19.08%
EBITDA	14,700	12,486	12,424	8,712	12,895	17,392
EBITDA Margin	16.79%	15.24%	17.15%	14.85%	22.50%	28.59%
D&A For EBITDA	4,445	3,977	4,238	3,463	2,423	2,585
EBIT	10,254	8,509	8,187	5,249	10,472	14,808
EBIT Margin	11.71%	10.39%	11.30%	8.95%	18.27%	24.34%
Effective Tax Rate	12.00%	14.69%	17.04%	26.60%	5.61%	22.14%
Advertising Expenses	-	2,032	1,515	364.81	100.36	70.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.